Department of Surgery in Galveston, University of Texas Medical Branch, Texas.
School of Medicine in Galveston, University of Texas Medical Branch, Texas.
Surg Obes Relat Dis. 2024 Dec;20(12):1198-1205. doi: 10.1016/j.soard.2024.06.010. Epub 2024 Jul 15.
Obesity, a known independent risk factor for developing malignancy. Additionally, renal transplant recipients (RTR) confer a 2- to 4-fold increased risk of overall malignancies with an excess absolute risk of .7% per year. While transplant recipients are at risk for obesity and malignancy, the effect of bariatric surgery (BS) in the posttransplantation setting is not well known.
Our study primarily evaluated the impact of BS on cancer incidence in RTR with severe obesity in the posttransplantation setting. Weight loss outcomes were analyzed secondarily.
University Hospital.
A retrospective study using TriNetX database was developed to analyze cancer outcomes in RTR with posttransplantation BS versus RTR without BS from 2000 to 2023. After the exclusion process and propensity matching, both cohorts consisted of 153 patients.
RTR-BS had a significantly lower incidence of overall cancer and transplant-related cancers (P < .05). No significant difference was identified in cutaneous, gastrointestinal, and reproductive cancers. Percent Excess Weight Loss (%EWL) was significantly lower in RTR-only cohort (11.4%) versus RTR-BS cohort (57.8%) at 5 years. Sleeve gastrectomy (SG) patients (73.19%) had significantly higher %EWL than Roux en-Y gastric bypass (RYGB) patients (49.33%) at 3 years. No difference in cancer incidence was noted between SG and RYGB patients.
Postrenal transplantation BS had a diminishing effect on overall and transplant-related cancer incidence in RTR with severe obesity. Significant weight loss was also demonstrated with post-renal transplantation BS.
肥胖是发生恶性肿瘤的已知独立危险因素。此外,肾移植受者(RTR)发生全身恶性肿瘤的风险增加 2-4 倍,年绝对超额风险为 0.7%。虽然移植受者存在肥胖和恶性肿瘤的风险,但在移植后进行减重手术(BS)的效果尚不清楚。
本研究主要评估了 BS 对移植后严重肥胖的 RTR 癌症发病率的影响。其次分析了减重效果。
大学医院。
使用 TriNetX 数据库进行回顾性研究,以分析 2000 年至 2023 年期间移植后接受 BS 与未接受 BS 的 RTR 的癌症结局。经过排除过程和倾向评分匹配后,两个队列均包括 153 名患者。
RTR-BS 的总体癌症和移植相关癌症的发生率明显较低(P<0.05)。皮肤、胃肠道和生殖系统癌症无显著差异。5 年时,仅 RTR 组的体重减轻百分比(%EWL)(11.4%)明显低于 RTR-BS 组(57.8%)。袖状胃切除术(SG)患者(73.19%)在 3 年内的 %EWL 明显高于 Roux-en-Y 胃旁路术(RYGB)患者(49.33%)。SG 和 RYGB 患者的癌症发病率无差异。
在严重肥胖的 RTR 中,肾移植后 BS 对总体和移植相关癌症的发病率有降低作用。肾移植后进行 BS 还可显著减轻体重。